A decline in NRF2 expression with age leads to an imbalance in the oxidative stress response, suggesting that the NRF2 pathway is a promising target for neurodegenerative disease therapy (Qin et al., 2024). This evidence concerns the gene NFE2L2 and neurodegenerative disease.